サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1420934

頭頸部がん市場：世界の業界分析、規模、シェア、成長、動向、予測、2023～2031年

Head and Neck Cancer Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 178 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
頭頸部がん市場：世界の業界分析、規模、シェア、成長、動向、予測、2023～2031年
出版日: 2023年12月18日
発行: Transparency Market Research
ページ情報: 英文 178 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

頭頸部がん市場- レポートの範囲

世界の頭頸部がん市場に関するTMRのレポートは、過去と現在の成長動向、および2023年から2031年の予測期間中に市場の指標の貴重な洞察を得る機会を研究しています。当レポートは、2023年を基準年、2031年を予測年とし、2017年から2031年の期間における世界市場の収益を提供します。また、2023年から2031年までの複合年間成長率（CAGR %）も提供します。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、頭頸部がん市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書の参照が含まれます。

市場スナップショット
2023年の市場価値 16億米ドル
2031年の市場価値 29億米ドル
CAGR 6.8%

このレポートは、世界の頭頸部がん市場の競合情勢を詳しく掘り下げています。世界の頭頸部がん市場で活動する主要企業が特定され、それぞれの企業がさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで紹介されている世界の頭頸部がん市場のプレーヤーの属性です。

目次

第1章 エグゼクティブサマリー

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • 市場セグメンテーション
  • 概要
  • 市場力学
  • 世界市場の分析と予測、2017～2031年

第5章 重要な洞察

  • パイプライン分析
  • 主要製品/ブランド分析
  • 主な合併と買収
  • COVID-19感染症のパンデミックが業界に与える影響

第6章 世界市場の分析と予測：薬剤クラス別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：薬剤クラス別、2017-2031
    • EGFR阻害剤
    • 有糸分裂阻害剤
    • 抗PD-1モノクローナル抗体
    • その他
  • 市場の魅力度：薬剤クラス別

第7章 世界市場の分析と予測：流通チャネル別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：流通チャネル別、2017-2031
    • 病院薬局
    • 小売薬局
    • eコマース
  • 市場の魅力：流通チャネル別

第8章 世界市場の分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2017-2031
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力：地域別

第9章 北米市場の分析と予測

第10章 欧州市場の分析と予測

第11章 アジア太平洋市場の分析と予測

第12章 ラテンアメリカ市場の分析と予測

第13章 中東およびアフリカ市場の分析と予測

第14章 競合情勢

  • 市場プレーヤー-競合マトリックス（企業の階層および規模別）
  • 市場シェア分析：企業別（2022年）
  • 企業プロファイル
    • Sanofi
    • Pfizer
    • Eli Lilly and Company
    • F. Hoffman-La Roche
    • AstraZeneca
    • Merck KgaA
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Galera
    • Fresenius Kabi
    • Teva Pharmaceuticals
図表

List of Tables

  • Table 1: Global Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 2: Global Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 3: Global Head and Neck Cancer Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 4: North America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 5: North America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 6: North America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 7: Europe Head and Neck Cancer Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 8: Europe Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 9: Europe Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel 2017-2031
  • Table 10: Asia Pacific Head and Neck Cancer Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 11: Asia Pacific Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 12: Asia Pacific Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 13: Latin America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Latin America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 15: Latin America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel 2017-2031
  • Table 16: Middle East & Africa Head and Neck Cancer Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Middle East & Africa Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 18: Middle East & Africa Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel 2017-2031

List of Figures

  • Figure 1: Global Head and Neck Cancer Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 2: Global Head and Neck Cancer Market Value Share, by Drug Class, 2022
  • Figure 3: Global Head and Neck Cancer Market Value Share, by Distribution Channel, 2022
  • Figure 4: Global Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 5: Global Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 6: Global Head and Neck Cancer Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 7: Global Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel 2023-2031
  • Figure 8: Global Head and Neck Cancer Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 9: Global Head and Neck Cancer Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 10: North America Head and Neck Cancer Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 11: North America Head and Neck Cancer Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 12: North America Head and Neck Cancer Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 13: North America Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 14: North America Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 15: North America Head and Neck Cancer Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 16: North America Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel 2023-2031
  • Figure 17: Europe Head and Neck Cancer Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 18: Europe Head and Neck Cancer Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 19: Europe Head and Neck Cancer Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 20: Europe Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 21: Europe America Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 22: Europe Head and Neck Cancer Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 23: Europe Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel 2023-2031
  • Figure 24: Asia Pacific Head and Neck Cancer Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 25: Asia Pacific Head and Neck Cancer Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 26: Asia Pacific Head and Neck Cancer Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 27: Asia Pacific Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 28: Asia Pacific America Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 29: Asia Pacific Head and Neck Cancer Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 30: Asia Pacific Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel 2023-2031
  • Figure 31: Latin America Head and Neck Cancer Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 32: Latin America Head and Neck Cancer Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 33: Latin America Head and Neck Cancer Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 34: Latin America Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 35: Latin America Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 36: Middle East & Africa Head and Neck Cancer Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 37: Middle East & Africa Head and Neck Cancer Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 38: Middle East & Africa America Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022-2031
  • Figure 39: Middle East & Africa America Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 40: Middle East & Africa Head and Neck Cancer Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 41: Middle East & Africa Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel 2023-2031
  • Figure 42: Global Head and Neck Cancer Market Share Analysis, by Company (2022)
目次
Product Code: TMRGL22919

Head and Neck Cancer Market - Scope of Report

TMR's report on the global head and neck cancer market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global head and neck cancer market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global head and neck cancer market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the head and neck cancer market.

Market Snapshot
Market Value in 2023US$ 1.6 Bn
Market Value in 2031US$ 2.9 Bn
CAGR6.8%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global head and neck cancer market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global head and neck cancer market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global head and neck cancer market.

The report delves into the competitive landscape of the global head and neck cancer market. Key players operating in the global head and neck cancer market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global head and neck cancer market profiled in this report.

Key Questions Answered in Global head and neck cancer Market Report:

  • What is the sales/revenue generated by head and neck cancer across all regions during the forecast period?
  • What are the opportunities in the global head and neck cancer market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Head and Neck Cancer Market - Research Objectives and Research Approach

The comprehensive report on the global head and neck cancer market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global head and neck cancer market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global head and neck cancer market.

Table of Contents

1. Executive Summary

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Head and Neck Cancer Market

4. Market Overview

  • 4.1. Market Segmentation
    • 4.1.1. Segment Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Head and Neck Cancer Market Analysis and Forecasts, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Head and Neck Cancer Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Class, 2017-2031
    • 6.3.1. EGFR Inhibitors
    • 6.3.2. Mitotic Inhibitors
    • 6.3.3. Anti-PD-1 Monoclonal Antibodies
    • 6.3.4. Others
  • 6.4. Market Attractiveness, by Drug Class

7. Global Head and Neck Cancer Market Analysis and Forecast, by Distribution Channel

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 7.3.1. Hospitals Pharmacies
    • 7.3.2. Retail Pharmacies
    • 7.3.3. E-commerce
  • 7.4. Market Attractiveness, by Distribution Channel

8. Global Head and Neck Cancer Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region, 2017-2031
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness, by Region

9. North America Head and Neck Cancer Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast, by Drug Class, 2017-2031
    • 9.2.1. EGFR Inhibitors
    • 9.2.2. Mitotic Inhibitors
    • 9.2.3. Anti-PD-1 Monoclonal Antibodies
    • 9.2.4. Others
  • 9.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 9.3.1. Hospitals Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. E-commerce
  • 9.4. Market Value Forecast, by Country, 2017-2031
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. Market Attractiveness Analysis
    • 9.5.1. By Drug Class
    • 9.5.2. By Distribution Channel
    • 9.5.3. By Country

10. Europe Head and Neck Cancer Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Drug Class, 2017-2031
    • 10.2.1. EGFR Inhibitors
    • 10.2.2. Mitotic Inhibitors
    • 10.2.3. Anti-PD-1 Monoclonal Antibodies
    • 10.2.4. Others
  • 10.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.3.1. Hospitals Pharmacies
    • 10.3.2. Retail Pharmacies
    • 10.3.3. E-commerce
  • 10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Italy
    • 10.4.5. Spain
    • 10.4.6. Rest of Europe
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Drug Class
    • 10.5.2. By Distribution Channel
    • 10.5.3. By Country/Sub-region

11. Asia Pacific Head and Neck Cancer Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Class, 2017-2031
    • 11.2.1. EGFR Inhibitors
    • 11.2.2. Mitotic Inhibitors
    • 11.2.3. Anti-PD-1 Monoclonal Antibodies
    • 11.2.4. Others
  • 11.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.3.1. Hospitals Pharmacies
    • 11.3.2. Retail Pharmacies
    • 11.3.3. E-commerce
  • 11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Drug Class
    • 11.5.2. By Distribution Channel
    • 11.5.3. By Country/Sub-region

12. Latin America Head and Neck Cancer Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2017-2031
    • 12.2.1. EGFR Inhibitors
    • 12.2.2. Mitotic Inhibitors
    • 12.2.3. Anti-PD-1 Monoclonal Antibodies
    • 12.2.4. Others
  • 12.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.3.1. Hospitals Pharmacies
    • 12.3.2. Retail Pharmacies
    • 12.3.3. E-commerce
  • 12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Drug Class
    • 12.5.2. By Distribution Channel
    • 12.5.3. By Country/Sub-region

13. Middle East & Africa Head and Neck Cancer Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Class, 2017-2031
    • 13.2.1. EGFR Inhibitors
    • 13.2.2. Mitotic Inhibitors
    • 13.2.3. Anti-PD-1 Monoclonal Antibodies
    • 13.2.4. Others
  • 13.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.3.1. Hospitals Pharmacies
    • 13.3.2. Retail Pharmacies
    • 13.3.3. E-commerce
  • 13.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.4.1. GCC Countries
    • 13.4.2. South Africa
    • 13.4.3. Rest of Middle East & Africa
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Drug Class
    • 13.5.2. By Distribution Channel
    • 13.5.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 14.2. Market Share Analysis, by Company (2022)
  • 14.3. Company Profiles
    • 14.3.1. Sanofi
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Product Portfolio
      • 14.3.1.3. Financial Overview
      • 14.3.1.4. SWOT Analysis
      • 14.3.1.5. Strategic Overview
    • 14.3.2. Pfizer
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Product Portfolio
      • 14.3.2.3. Financial Overview
      • 14.3.2.4. SWOT Analysis
      • 14.3.2.5. Strategic Overview
    • 14.3.3. Eli Lilly and Company
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Product Portfolio
      • 14.3.3.3. Financial Overview
      • 14.3.3.4. SWOT Analysis
      • 14.3.3.5. Strategic Overview
    • 14.3.4. F. Hoffman-La Roche
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Product Portfolio
      • 14.3.4.3. Financial Overview
      • 14.3.4.4. SWOT Analysis
      • 14.3.4.5. Strategic Overview
    • 14.3.5. AstraZeneca
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Product Portfolio
      • 14.3.5.3. Financial Overview
      • 14.3.5.4. SWOT Analysis
      • 14.3.5.5. Strategic Overview
    • 14.3.6. Merck KgaA
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Product Portfolio
      • 14.3.6.3. Financial Overview
      • 14.3.6.4. SWOT Analysis
      • 14.3.6.5. Strategic Overview
    • 14.3.7. Bayer AG
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Product Portfolio
      • 14.3.7.3. Financial Overview
      • 14.3.7.4. SWOT Analysis
      • 14.3.7.5. Strategic Overview
    • 14.3.8. Bristol-Myers Squibb Company
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Product Portfolio
      • 14.3.8.3. Financial Overview
      • 14.3.8.4. SWOT Analysis
      • 14.3.8.5. Strategic Overview
    • 14.3.9. Galera
      • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.9.2. Product Portfolio
      • 14.3.9.3. Financial Overview
      • 14.3.9.4. SWOT Analysis
      • 14.3.9.5. Strategic Overview
    • 14.3.10. Fresenius Kabi
      • 14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.10.2. Product Portfolio
      • 14.3.10.3. Financial Overview
      • 14.3.10.4. SWOT Analysis
      • 14.3.10.5. Strategic Overview
    • 14.3.11. Teva Pharmaceuticals
      • 14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.11.2. Product Portfolio
      • 14.3.11.3. Financial Overview
      • 14.3.11.4. SWOT Analysis
      • 14.3.11.5. Strategic Overview